- Home
- HUMA vs DHF Comparison
HUMA vs DHF Comparison
Compare HUMA & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HUMA | DHF |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.7M | 159.3M |
| IPO Year | 2020 | 1998 |
Fundamental Metrics
Financial Performance| Metric | HUMA | DHF |
|---|---|---|
| Price | $0.43 | $2.22 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.63 | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 446.8K |
| Earning Date | 11-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,038,000.00 | N/A |
| Revenue This Year | $72.32 | N/A |
| Revenue Next Year | $518.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $2.12 |
| 52 Week High | $1.90 | $2.59 |
Technical Indicators
Market Signals| Indicator | HUMA | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 43.11 |
| Support Level | N/A | $2.12 |
| Resistance Level | $0.75 | $2.45 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 47.46 | 64.71 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.